Keywords: oxigene, zybrestat, achieves, endpoints, ovarian, cancer, clinical-stage

OXiGENE's Zybrestat achieves endpoints in ovarian cancer

Article | 07 January 2008

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, says that its lead product candidate, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Carboplatin

Paraplatin

Paclitaxel

Taxol

Go to drug listing